Pharnext SA represents a commitment to innovation and excellence in the biopharmaceutical industry. With a strong focus on research and development, the company strives to provide groundbreaking solutions to medical challenges. Pharnext prioritizes the improvement of patient lives through its unique business model, which combines conventional pharmaceutical approaches with advanced big data analytics. By leveraging cutting-edge technology and collaboration with industry experts, Pharnext aims to accelerate the discovery and development of new treatments for various diseases. The company's dedication to scientific advancement and a patient-centric approach truly sets Pharnext SA apart in the biopharmaceutical landscape.

Pharnext SA is primarily present in France.

Pharnext SA, a leading pharmaceutical company, has achieved several significant milestones. One notable achievement is the successful completion of its Phase 3 clinical trial for PXT3003, a potential treatment for Charcot-Marie-Tooth disease type 1A (CMT1A). The positive results obtained during this trial have opened doors for Pharnext SA to further advance its development and seek regulatory approval. Moreover, the company has formed strategic collaborations with renowned institutions and industry partners to accelerate research and development efforts. Pharnext SA's commitment to innovation and dedication to addressing critical medical needs reaffirm its position as a prominent player in the pharmaceutical industry.

Pharnext SA is a renowned biopharmaceutical company, specializing in the development and commercialization of innovative drugs. Established in 2007, Pharnext SA has rapidly emerged as a key player in the healthcare industry. Their dedicated team of experts combines cutting-edge science with advanced technologies to create effective treatments for a wide range of diseases. With a strong focus on neurological disorders and orphan diseases, Pharnext SA diligently works toward improving patients' lives and addressing unmet medical needs. Through strategic collaborations and extensive research, the company aims to revolutionize the healthcare landscape by delivering breakthrough therapies and making a lasting impact on global health.

The main competitors of Pharnext SA in the market include pharmaceutical companies such as Novartis, Pfizer, and Sanofi. These companies also operate in the biotechnology sector, focusing on innovation and drug development. With Pharnext SA's expertise in the development of innovative treatments, it competes directly with these industry giants in establishing its presence and gaining market share. Despite the competition, Pharnext SA continues to differentiate itself by leveraging its unique approach to drug discovery and strategic collaborations, enabling it to create value for patients and stakeholders.

Pharnext SA is primarily active in the pharmaceutical industry.

The business model of Pharnext SA is focused on biopharmaceutical research and development. Pharnext conducts innovative research to identify and develop new drug combinations for various medical conditions. By leveraging its proprietary technology platform, Pharnext aims to accelerate the discovery and development of effective treatments. The company collaborates with partners in academia, biotech, and pharmaceutical industries to advance its research programs. With a strong emphasis on precision medicine, Pharnext aims to improve patient outcomes by targeting multiple pathways and addressing complex diseases. Through its holistic approach and extensive expertise, Pharnext strives to deliver high-value therapeutic solutions to improve the lives of patients.

Pharnext KGV yra −0,00.

Pharnext KUV yra 0,00.

AlleAktien kokybės įvertis Pharnext yra 5/10.

tikėtina Pharnext pardavimai yra 9,22 mln. EUR.

tikėtina Pharnext pelnas yra −582,38 mlrd. EUR.

Pharnext SA is a biopharmaceutical company based in France that focuses on developing therapies for the treatment of rare diseases. They use a patented technology platform called Pleotherapy to combine multiple approved drugs and create new treatments with improved safety, efficacy, and duration. Their business activities are divided into research and development, marketing and sales, and clinical development. They aim to provide innovative and effective therapeutic treatments that reduce healthcare costs and benefit patients. Overall, Pharnext's business model is innovative and shows potential for investors and the healthcare sector.

Pharnext moka dividendą 0 EUR, kuris yra paskirstytas per išmokas per metus.

Dividenda šiuo metu negali būti apskaičiuota Pharnext arba įmonė dividendų nemoka.

Pharnext ISIN yra FR0011191287.

Pharnext WKN yra A2AM02.

Pharnext akcijų simbolis yra ALPHA.PA.

Per paskutinius 12 mėnesių Pharnext išmokėjo dividendą, kurios dydis siekė . Tai atitinka maždaug dividendų grąžą. Artimiausiems 12 mėnesiams Pharnext tikėtina išmokės dividendus, kurie sudarys 0 EUR.

Pharnext šiuo metu yra dydžio dividendų grąža.

Pharnext moka dividendus kas ketvirtį. Jie išmokami mėnesiais.

Pharnext per paskutiniuosius 0 metus kiekvienais metais mokėjo dividendus.

Artimiausiems 12 mėnesiams tikimasi dividendų, kurių dydis yra 0 EUR. Tai atitinka 0 % dividendų grąžos procentą.

Pharnext priskiriamas sektoriui "Sveikata".

Norėdamas gauti paskutinį Pharnext dividendą nuo 2024-11-05, kurio dydis yra 0 EUR, turėjai turėti akciją savo depozite prieš ex-dieną, kuri buvo 2024-11-05.

Paskutinės dividendų išmokėjimas įvyko 2024-11-05.

2023 metais Pharnext išmokėjo 0 EUR dividendų.

Pharnext dividendai yra mokami EUR.